{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:04:44Z","timestamp":1778875484634,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10552-021-01521-2","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T19:37:10Z","timestamp":1638301030000},"page":"343-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-063X","authenticated-orcid":false,"given":"Yee Yee","family":"Yap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameela","family":"Sathar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian Boon","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"MPN registry working group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen Mui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngee Siang","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tee Chuan","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai Sim","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng Keat","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See Guan","family":"Toh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier Yoon Han","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmini","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Khee","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azlan Bin","family":"Husin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Lee Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee Ping","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinari","family":"Salleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Yen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin Wah","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Hong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Carlo","family":"Edmund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenq Tzong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin Gin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Yegappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian Meng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"issue":"S1","key":"1521_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/ijlh.12509","volume":"38","author":"JT Geyer","year":"2016","unstructured":"Geyer JT, Orazi A (2016) Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic\/myeloproliferative neoplasms: current diagnostic principles and upcoming updates. Int J Lab Hematol 38(S1):12\u201319. https:\/\/doi.org\/10.1111\/ijlh.12509","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"1521_CR2","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","volume":"107","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Griesshammer M, D\u00f6hner K, D\u00f6hner H, Kusec R, Hasselbalch HC et\u00a0al (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107(5):2098\u20132100. https:\/\/doi.org\/10.1182\/blood-2005-08-3395","journal-title":"Blood"},{"issue":"12","key":"1521_CR3","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E et\u00a0al (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12):4030\u20134036. https:\/\/doi.org\/10.1182\/blood-2007-07-099184","journal-title":"Blood"},{"issue":"3","key":"1521_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","volume":"131","author":"A Tefferi","year":"2005","unstructured":"Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li C-Y et\u00a0al (2005) The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131(3):320\u2013328. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05776.x","journal-title":"Br J Haematol"},{"issue":"13","key":"1521_CR5","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et\u00a0al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment. Blood 113(13):2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"issue":"6","key":"1521_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M (2017) Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129(6):680\u2013692. https:\/\/doi.org\/10.1182\/blood-2016-10-695957","journal-title":"Blood"},{"issue":"26","key":"1521_CR7","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et\u00a0al (2012) Development and validation of an international prognostic score of thrombosis in world health organization\u2013essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133. https:\/\/doi.org\/10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"issue":"9","key":"1521_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et\u00a0al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881. https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"9","key":"1521_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et\u00a0al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International working group for myeloproliferative neoplasms research and treatment). Blood 115(9):1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"4","key":"1521_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et\u00a0al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. JCO 29(4):392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"JCO"},{"issue":"1","key":"1521_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-018-0124-7","volume":"7","author":"YY Yap","year":"2018","unstructured":"Yap YY, Law KB, Sathar J, Lau NS, Goh AS, Chew TK et\u00a0al (2018) The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Exp Hematol Oncol 7(1):31. https:\/\/doi.org\/10.1186\/s40164-018-0124-7","journal-title":"Exp Hematol Oncol"},{"key":"1521_CR12","unstructured":"R Core Team (2021) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. www.R-project.org"},{"issue":"24","key":"1521_CR13","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM-L, Landgren O, Eloranta S, Derolf \u00c5R et\u00a0al (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. JCO 30(24):2995\u20133001. https:\/\/doi.org\/10.1200\/JCO.2012.42.1925","journal-title":"JCO"},{"key":"1521_CR14","doi-asserted-by":"crossref","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105(7):2664\u20132670. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120456599. Accessed 15 Sept 2020","DOI":"10.1182\/blood-2004-09-3426"},{"issue":"3","key":"1521_CR15","doi-asserted-by":"publisher","first-page":"e90299","DOI":"10.1371\/journal.pone.0090299","volume":"9","author":"GL Price","year":"2014","unstructured":"Price GL, Davis KL, Karve S, Pohl G, Walgren RA (2014) Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS ONE 9(3):e90299. https:\/\/doi.org\/10.1371\/journal.pone.0090299","journal-title":"PLoS ONE"},{"issue":"10","key":"1521_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et\u00a0al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755\u2013761. https:\/\/doi.org\/10.1016\/j.amjmed.2004.06.032","journal-title":"Am J Med"},{"issue":"3","key":"1521_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/bjh.14061","volume":"174","author":"SA Srour","year":"2016","unstructured":"Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS et\u00a0al (2016) Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312. Br J Haematol 174(3):382\u2013396. https:\/\/doi.org\/10.1111\/bjh.14061","journal-title":"Br J Haematol"},{"key":"1521_CR18","doi-asserted-by":"crossref","unstructured":"Boren E, Gershwin ME (2004) Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmunity Rev 3(5):401\u20136. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997204000424. Accessed 15 Sept 2020","DOI":"10.1016\/j.autrev.2004.03.004"},{"issue":"6917","key":"1521_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860\u2013867. https:\/\/doi.org\/10.1038\/nature01322","journal-title":"Nature"},{"key":"1521_CR20","first-page":"102","volume":"18","author":"H Geyer","year":"2016","unstructured":"Geyer H, Kosiorek H, Dueck A, Scherber R, Slot S, Zweegman S et\u00a0al (2016) Associations between gender, disease features and symptom burden in the MPN population: an analysis by the MPN QOL international working group. Haematologica 18:102","journal-title":"Haematologica"},{"key":"1521_CR21","doi-asserted-by":"crossref","unstructured":"Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al (2009) Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 18(4):1174. http:\/\/cebp.aacrjournals.org\/content\/18\/4\/1174.abstract. Accessed 15 Sept 2020","DOI":"10.1158\/1055-9965.EPI-08-1118"},{"issue":"105","key":"1521_CR22","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"1","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 1(105):1684\u20131692","journal-title":"Br J Cancer"},{"issue":"11","key":"1521_CR23","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood-2011-11-389866","volume":"119","author":"Z Xu","year":"2012","unstructured":"Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P et\u00a0al (2012) Unique features of primary myelofibrosis in Chinese. Blood 119(11):2469\u20132473. https:\/\/doi.org\/10.1182\/blood-2011-11-389866","journal-title":"Blood"},{"key":"1521_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1182\/asheducation.V2016.1.552.088349","volume":"1","author":"JM Shammo","year":"2016","unstructured":"Shammo JM, Stein BL (2016) Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions. Hematology 1:552\u2013560. https:\/\/doi.org\/10.1182\/asheducation.V2016.1.552.088349","journal-title":"Hematology"},{"key":"1521_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/asheducation-2016.1.534","volume":"1","author":"F Passamonti","year":"2016","unstructured":"Passamonti F, Maffioli M (2016) Update from the latest WHO classification of MPNs: a user\u2019s manual. Hematology 1:534\u2013542. https:\/\/doi.org\/10.1182\/asheducation-2016.1.534","journal-title":"Hematology"},{"issue":"5","key":"1521_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Pereira A, Kerguelen A, Carlos Hern\u00e1ndez-Boluda J, Mart\u00ednez-Avil\u00e9s L et\u00a0al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517\u2013523. https:\/\/doi.org\/10.1002\/ajh.23676","journal-title":"Am J Hematol"},{"issue":"2","key":"1521_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","volume":"86","author":"K Abdulkarim","year":"2011","unstructured":"Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andr\u00e9asson B (2011) The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 86(2):148\u2013155. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01548.x","journal-title":"Eur J Haematol"},{"issue":"1","key":"1521_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2040620710394474","volume":"2","author":"AM Vannucchi","year":"2011","unstructured":"Vannucchi AM, Pieri L, Guglielmelli P (2011) JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Ther Adv Hematol 2(1):21\u201332. https:\/\/doi.org\/10.1177\/2040620710394474","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"1521_CR29","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E et\u00a0al (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114(8):1477\u20131483. https:\/\/doi.org\/10.1182\/blood-2009-04-216044","journal-title":"Blood"},{"issue":"4","key":"1521_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY et\u00a0al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22(4):756\u2013761. https:\/\/doi.org\/10.1038\/sj.leu.2405097","journal-title":"Leukemia"},{"issue":"4","key":"1521_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/leu.2014.8","volume":"28","author":"CD DiNardo","year":"2014","unstructured":"DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC et\u00a0al (2014) Myelodysplastic\/myeloproliferative neoplasms, unclassifiable (MDS\/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958\u2013961","journal-title":"Leukemia"},{"key":"1521_CR32","doi-asserted-by":"crossref","unstructured":"Chaudhury A, Komrokji RS, Al Ali NH, Zhang L, Vafaii P, Lancet JE (2015) Prognosis and outcomes in MDS-MPN unclassifiable: single institution experience of a rare disorder. Blood 126(23):1698. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497118486776","DOI":"10.1182\/blood.V126.23.1698.1698"},{"issue":"12","key":"1521_CR33","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1038\/bcj.2016.116","volume":"6","author":"B Li","year":"2016","unstructured":"Li B, Zhang P, Feng G, Xu Z, Qin T, Zhang Y et\u00a0al (2016) Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. Blood Cancer J 6(12):e505\u2013e505. https:\/\/doi.org\/10.1038\/bcj.2016.116","journal-title":"Blood Cancer J"},{"issue":"9","key":"1521_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, Rotunno G, Pacilli A, Rumi E, Rosti V, Delaini F et\u00a0al (2016) Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol 91(9):918\u2013922. https:\/\/doi.org\/10.1002\/ajh.24442","journal-title":"Am J Hematol"},{"issue":"10","key":"1521_CR35","doi-asserted-by":"publisher","first-page":"E454","DOI":"10.1002\/ajh.24458","volume":"91","author":"MA Elliott","year":"2016","unstructured":"Elliott MA, Tefferi A (2016) The prognostic impact of bone marrow fibrosis in primary myelofibrosis. Am J Hematol 91(10):E454\u2013E454. https:\/\/doi.org\/10.1002\/ajh.24458","journal-title":"Am J Hematol"},{"issue":"2","key":"1521_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/sj.leu.2404500","volume":"21","author":"N Gangat","year":"2007","unstructured":"Gangat N, Wolanskyj AP, McClure RF, Li C-Y, Schwager S, Wu W et\u00a0al (2007) Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 21(2):270\u2013276. https:\/\/doi.org\/10.1038\/sj.leu.2404500","journal-title":"Leukemia"},{"issue":"2","key":"1521_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Barbui T (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90(2):162\u2013173. https:\/\/doi.org\/10.1002\/ajh.23895","journal-title":"Am J Hematol"},{"issue":"6","key":"1521_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et\u00a0al (2012) A prognostic model to predict survival in 867 World health organization\u2013defined essential thrombocythemia at diagnosis: a study by the International working group on myelofibrosis research and treatment. Blood 120(6):1197\u20131201. https:\/\/doi.org\/10.1182\/blood-2012-01-403279","journal-title":"Blood"},{"issue":"12","key":"1521_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A (2018) Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93(12):1551\u20131560. https:\/\/doi.org\/10.1002\/ajh.25230","journal-title":"Am J Hematol"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-021-01521-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-021-01521-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T12:29:32Z","timestamp":1642681772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-021-01521-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s10552-021-01521-2","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The registry and study received approval from the Medical Research & Ethics Committee in 2017 (registration no. NMRR-17-2250-37701).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}